Insilico Medicine
Commercial
About
Insilico Medicine is a clinical-stage biotechnology company that applies generative AI to drug discovery through its Pharma.AI platform, spanning target discovery (PandaOmics), generative molecule design (Chemistry42) and clinical-outcome prediction (inClinico). It develops an internal pipeline of small-molecule candidates in fibrosis, oncology, immunology and other areas, and earns revenue from out-licensing, co-development and research collaborations and from software. Founded in 2014 with early work on AI biomarkers of aging, it links target discovery to aging biology and states a mission to extend healthy longevity. Its lead candidate, rentosertib, an AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis, entered a 52-week Phase III trial in China (GENESIS-IPF-3), with the first patient dosed in September 2026; it remains investigational. The company listed on the Main Board of the Hong Kong Stock Exchange (3696.HK) on 30 December 2025.
Rating breakdown
Aggregate 90/100 · rank #1 in the commercial table full ratings →
Expand a signal to see what contributes to it.
Publications87
- Alex Zhavoronkov — h-index 79 source ↗
- Alex Aliper — h-index 51 source ↗
- Feng Ren — h-index 30 source ↗
- Fedor Galkin — h-index 15 source ↗
- An open benchmark and language models for AI in aging biology (Cell; LongevityBench, Longevity-LLMs, LongevityClaw) ↗
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment (Nature Biotechnology; rentosertib) ↗
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (Nature Medicine) ↗
- A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models (Nature Biotechnology) ↗
- Deep biomarkers of human aging: application of deep neural networks to biomarker development (Aging) ↗
Discovery100
Trials from ClinicalTrials.gov (this org as lead sponsor), matched to aging by their condition or intervention.
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) ↗ PHASE3 · Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis ↗ PHASE2 · Idiopathic Pulmonary Fibrosis (IPF)
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) ↗ PHASE2 · Idiopathic Pulmonary Fibrosis (IPF)
- A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects ↗ PHASE1 · Idiopathic Pulmonary Fibrosis
- GENESIS-IPF-3: first patient dosed in Phase III trial of rentosertib (TNIK inhibitor) in idiopathic pulmonary fibrosis ↗
- MMAI Gym for Science: life-science foundation-model training framework (Jan 2026) and release of SOTA chemistry/biology specialist models (Sept 2026) ↗
- ISM6331 (AI-designed pan-TEAD inhibitor): FDA Fast Track Designation in advanced mesothelioma; first-in-human Phase I data accepted as ESMO 2026 rapid oral ↗
- ISM8969/HT-001 (brain-penetrant NLRP3 inhibitor, co-developed with Hygtia): first-in-human dosing in Phase I ↗
- Shanghai Fosun Pharmaceutical — co-development source ↗
- Sanofi — collaboration · USD 1.20B source ↗
- Exelixis — licensing source ↗
- Menarini Group / Stemline Therapeutics — licensing · USD 500M source ↗
- Menarini Group / Stemline Therapeutics — licensing · USD 550M source ↗
- Servier — collaboration · USD 888M source ↗
Development81
Clinical-phase depth of the same aging-relevant trials (later phase weighs more).
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) ↗ PHASE3 · Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis ↗ PHASE2 · Idiopathic Pulmonary Fibrosis (IPF)
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) ↗ PHASE2 · Idiopathic Pulmonary Fibrosis (IPF)
- A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects ↗ PHASE1 · Idiopathic Pulmonary Fibrosis
Fundraising81
- Market cap HKD 33.77B · 3696.HK (2026-09-23) source ↗
- 2019-09 — Insilico Medicine publicly disclosed Series B financing (2019) · USD 37M · Qiming Venture Partners (lead), Eight Roads, F-Prime Capital, Lilly Asia Ventures source ↗
- 2021-06 — Insilico Medicine publicly disclosed Series C financing (2021) · USD 255M · Warburg Pincus (lead) source ↗
- 2022-06 — Insilico Medicine publicly disclosed Series D financing (2022) · USD 60M · Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners source ↗
- 2022-08 — Insilico Medicine publicly disclosed Series D2 extension (2022) · USD 35M · Prosperity7 Ventures (Aramco Ventures; lead) source ↗
- 2025-03 — Insilico Medicine publicly disclosed Series E financing (2025) · USD 110M · Value Partners Group private equity fund (lead) source ↗
- Cumulative deal value USD 11.00B source ↗
- Completed an IPO source ↗
Education100
- Alex Zhavoronkov public communicator
- Alex Zhavoronkov ARDD speaker 2024;2025;2026 source ↗
- Fedor Galkin ARDD speaker 2024 source ↗
- Frank Pun ARDD speaker 2024 source ↗
- Christopher Ren ARDD speaker 2024 source ↗
- Garri Zmudze ARDD speaker 2024;2025;2026 source ↗
- Aisyah Sjöholm ARDD speaker 2025 source ↗
- Chuen Yan Leung ARDD speaker 2025;2026 source ↗
- Anastasia Georgievskaya ARDD speaker 2025 source ↗
- Conference organiser / co-chair role (e.g. ARDD)
- Science42: DORA ↗ open tool / resource
- MMAI Gym for Science ↗ open tool / resource
- Longevity AI toolkit (LongevityBench, Longevity-LLMs, Longevity Claw) ↗ open tool / resource
- TargetPro / TargetBench ↗ open tool / resource
- DDD Bench (Drug Discovery and Development Benchmark) ↗ open tool / resource
Key outputs
- clinical trial GENESIS-IPF-3: first patient dosed in Phase III trial of rentosertib (TNIK inhibitor) in idiopathic pulmonary fibrosis ↗ 2026
- publication An open benchmark and language models for AI in aging biology (Cell; LongevityBench, Longevity-LLMs, LongevityClaw) ↗ 2026
- publication Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment (Nature Biotechnology; rentosertib) ↗ 2026
- product MMAI Gym for Science: life-science foundation-model training framework (Jan 2026) and release of SOTA chemistry/biology specialist models (Sept 2026) ↗ 2026
- drug candidate ISM6331 (AI-designed pan-TEAD inhibitor): FDA Fast Track Designation in advanced mesothelioma; first-in-human Phase I data accepted as ESMO 2026 rapid oral ↗ 2026
- clinical trial ISM8969/HT-001 (brain-penetrant NLRP3 inhibitor, co-developed with Hygtia): first-in-human dosing in Phase I ↗ 2026
- publication A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (Nature Medicine) ↗ 2025
- publication A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models (Nature Biotechnology) ↗ 2024
- publication Deep biomarkers of human aging: application of deep neural networks to biomarker development (Aging) ↗ 2016
Registered clinical trials
11 trials list this organisation as lead sponsor ClinicalTrials.gov ↗
- Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors ↗ PHASE1 · NOT_YET_RECRUITING · 2026-12-30
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) ↗ PHASE3 · RECRUITING · 2026-09-09
- A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969 ↗ PHASE1 · RECRUITING · 2026-06-15
- Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) ↗ PHASE2 · RECRUITING · 2025-12-10
- Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors ↗ PHASE1, PHASE2 · RECRUITING · 2025-04-25
- Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors ↗ PHASE1, PHASE2 · RECRUITING · 2024-12-27
- Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma ↗ PHASE1 · RECRUITING · 2024-04-25
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis ↗ PHASE2 · RECRUITING · 2024-02-08
Showing 8 of 11 registered trials.
Financial
Financing rounds
| Date | Amount | Round | Investors |
|---|---|---|---|
| 2019-09 | USD 37M | Insilico Medicine publicly disclosed Series B financing (2019) | Qiming Venture Partners (lead), Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners |
| 2021-06 | USD 255M | Insilico Medicine publicly disclosed Series C financing (2021) | Warburg Pincus (lead) |
| 2022-06 | USD 60M | Insilico Medicine publicly disclosed Series D financing (2022) | Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, BHR Partners, a US West Coast asset manager (unnamed) |
| 2022-08 | USD 35M | Insilico Medicine publicly disclosed Series D2 extension (2022) | Prosperity7 Ventures (Aramco Ventures; lead) |
| 2025-03 | USD 110M | Insilico Medicine publicly disclosed Series E financing (2025) | Value Partners Group private equity fund (lead) |
Recent deals & partnerships
| Date | Partner | Type | Headline value |
|---|---|---|---|
| 2022-01 | Shanghai Fosun Pharmaceutical | co-development | undisclosed |
| 2022-11 | Sanofi | collaboration | USD 1.20B |
| 2023-09 | Exelixis | licensing | undisclosed |
| 2024-01 | Menarini Group / Stemline Therapeutics | licensing | USD 500M |
| 2025-01 | Menarini Group / Stemline Therapeutics | licensing | USD 550M |
| 2026-01 | Servier | collaboration | USD 888M |
| 2026-03 | Eli Lilly and Company | licensing | USD 2.75B |
| 2026-06 | SK Biopharmaceuticals | collaboration | USD 2.50B |
| 2026-07 | Takeda | collaboration | USD 600M |
| 2026-07 | China Medical System Holdings | collaboration | CNY 1.20B |
Headline values are potential totals (mostly contingent milestones), not cash received.
Key people
Alex ZhavoronkovFounder; Chairman of the Board, Executive Director, CEO and CBO (Chief Business Officer)Feng RenChief Scientific Officer, Executive Director and Co-CEOAlex AliperPresidentPetrina KamyaVice President, Global Head of AI Platforms, and President of Insilico Medicine CanadaFedor GalkinDirector of AI Longevity Research
Research fields
Links
Sources
- https://insilico.com/about
- https://insilico.com/team
- https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html
- https://www.prnewswire.com/news-releases/insilico-medicine-raises-255-million-in-series-c-financing-led-by-warburg-pincus-301317145.html
- https://clinicaltrials.gov/study/NCT05938920
- https://doi.org/10.1038/s41591-025-03743-2
- https://doi.org/10.1038/s41587-024-02143-0
- https://doi.org/10.1038/s41587-019-0224-x
- https://doi.org/10.18632/aging.100968
- https://ir.insilico.com/media/b4thx2ea/2026-interim-report-en.pdf
- https://stockanalysis.com/quote/hkg/3696/market-cap/
- https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3
- https://doi.org/10.1016/j.cell.2026.08.026
- https://doi.org/10.1038/s41587-026-03286-y
- https://insilico.com/news/tvb0jud0y1-insilico-medicine-releases-sota-mmai-spe
- https://insilico.com/news/034jeh2rl1-insilico-medicine-receives-fda-fast-trac
- https://insilico.com/news/bno2kl4lp1-insilico-completes-first-in-human-dosing
- https://pharma.ai
- https://pharma.ai/pandaomics
- https://insilico.com/news/spjz8fzmb1-insilico-medicine-launches-pandaclaw-emp
- https://pharma.ai/chemistry42
- https://pharma.ai/generativebiologics
- https://pharma.ai/inclinico
- https://pharma.ai/dora
- https://pharma.ai/nach01
- https://pharma.ai/precious
- https://insilico.com/mmai
- https://virtualcell.insilico.com/
- https://insilico.com/news/cell170926en-ai-longevity-discovery-toolkit
- https://insilico.com/news/77g216v1e1-insilico-medicine-advances-ai-driven-tar
- https://insilico.com/news/pr84b6b87c28897f2c680e-pharma-ai-2026-fall-update-preview-agentic-ai-takes-the-wheel-of-pharmaceutical-intelligence